FRANKFURT (Reuters) - Merck KGaA's Cilengitide, an experimental drug to treat an aggressive type of brain tumor, has failed a large-scale clinical trial, dealing a blow to the German drugmaker's efforts to replenish its pipeline of medicines. Merck said on Monday patients in a Phase III trial did not live significantly longer when treated with Cilengitide plus chemoradiotherapy. Dr. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment